Richard Woessner

Rich Woessner is Senior Vice President of Pharmacology at OnKure, Inc. working with the scientific team to develop and implement in vivo pharmacology strategies to discover compounds. He has over 30 years of experience in oncology drug discovery and pre-clinical pharmacology and has held roles at numerous biotech and at large pharmaceutical companies, including Sanofi, MedImmune, Array BioPharma, AstraZeneca, and Blueprint Medicines. He has led the preclinical in vivo pharmacology effort on multiple projects that have resulted in advancing compounds into the clinic, such as ipatasertib (AKT inhibitor), filanesib (KSP inhibitor), AZD4205 (JAK1 inhibitor), and danvatirsen (STAT3 inhibitor). Dr. Woessner did his postdoctoral training at SmithKline Beecham, where he studied the biology of topisomerases I and II and mechanisms of resistance to the topoisomerase I inhibitor, topotecan, and received a Ph.D. in Biochemistry from the University of Illinois.